Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

Journal Articles

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update

Michael T. Byrne, DO, Donya Salmasinia, MSc, Helen Leather, BPharm, Amy Davis, MSc, Jack W. Hsu, MD, Laura Wiggins, PharmD, Christopher R. Cogle, MD, Myron N Chang, PhD, John R. Wingard, MD, Jan S Moreb, MD

Blood (2012) 120 (21): 2023.

https://doi.org/10.1182/blood.V120.21.2023.2023

Published: 2012

Journal Articles

Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.

Asha R. Dhanarajan, MD, Jack W Hsu, MD, John R. Wingard, MD, Myron N Chang, PhD, Consuela Soldevila-Pico, MD, Shehzad Rehman, MD, Maher Baz, MD, Maxim Norkin, MD, PhD

Blood (2012) 120 (21): 2799.

https://doi.org/10.1182/blood.V120.21.2799.2799

Published: 2012

Journal Articles

Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT)

Napoleon Santos, DO, Randy A. Brown, MD, Myron N Chang, PhD, Christopher R Cogle, M.D., John W. Hiemenz, MD, W. Stratford May, Jan S Moreb, MD, Maxim Norkin, MD, PhD, John R. Wingard, MD, Baldeep Wirk, MD, Jack W Hsu, MD

Blood (2011) 118 (21): 4462.

https://doi.org/10.1182/blood.V118.21.4462.4462

Published: 2011

Journal Articles

CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia

Sukanthini Subbiah, MD, Randy A. Brown, MD, Myron N Chang, PhD, Christopher R Cogle, M.D., John W. Hiemenz, MD, W. Stratford May, MD, PhD, Jan Moreb, MD, Maxim Norkin, MD, PhD, John R. Wingard, MD, Baldeep Wirk, MD, Jack W Hsu, MD

Blood (2011) 118 (21): 4299.

https://doi.org/10.1182/blood.V118.21.4299.4299

Published: 2011

Journal Articles

Wilm’s Tumor 1 Gene Expression Is a Useful Marker for Minimal Residual Disease in Acute Myeloid Leukemia.

Jack W. Hsu, MD, Hong Liu, MD, Katarzyna Jamieson, MD, Wei Hou, PhD, Myron N. Chang, PhD, Kim P. Ahrens, Raul C. Braylan, MD, John R. Wingard, MD

Blood (2007) 110 (11): 4240.

https://doi.org/10.1182/blood.V110.11.4240.4240

Published: 2007

Journal Articles

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman J. Lacayo, MD, Maureen O’Brien, MD, Shweta Jain, Soheil Meshinchi, MD, PhD, Ron Yu, PhD, Dejan Juric, MD, Myron N. Chang, PhD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 1915.

https://doi.org/10.1182/blood.V108.11.1915.1915

Published: 2006

Journal Articles

Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Retrospective Study.

Hong Liu, MD, PhD, Constance M. Yuan, MD, Raul C. Braylan, MD, Myron N. Chang, PhD, John R. Wingard, MD, Jan S. Moreb, MD

Blood (2006) 108 (11): 5014.

https://doi.org/10.1182/blood.V108.11.5014.5014

Published: 2006

Journal Articles

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Don Hoang, Dejan Juric, MD, Susana C. Raimondi, PhD, David Chen, Myron N. Chang, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2771.

https://doi.org/10.1182/blood.V106.11.2771.2771

Published: 2005

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

NARROW

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update

Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.

Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT)

CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia

Wilm’s Tumor 1 Gene Expression Is a Useful Marker for Minimal Residual Disease in Acute Myeloid Leukemia.

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Retrospective Study.

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only